title: Dinoprostone vaginal insert versus intravenous oxytocin to reduce postpartum blood loss following vaginal or cesarean delivery.
abstract: OBJECTIVE
  To compare the impact of a dinoprostone vaginal insert and intravenous oxytocin in reducing blood loss of women undergoing vaginal or cesarean delivery.
  
  
  METHODS
  This study was conducted among term singleton pregnancies delivered vaginally or by elective cesarean section. In the vaginally delivered cases, active management of the third stage of labor was conducted. During cesarean delivery, 20 IU of intravenous oxytocin was administered. Women, who either delivered via the vaginal or abdominal route, were then randomly allocated to receive 10 mg vaginal dinoprostone insert for 12 hours (group I, n: 100) or intravenous oxytocin (group II, n: 100), respectively.
  
  
  RESULTS
  Mean blood loss and need for additional uterotonics and postpartum hemoglobin and hematocrit levels at 24 and 36 hours after delivery did not differ between the two groups. Women allocated to the dinoprostone vaginal insert arm experienced more nausea and vomiting.
  
  
  CONCLUSIONS
  Dinoprostone vaginal insert was as effective as intravenous oxytocin in the prevention of postpartum blood loss.
authors.affiliation: Department of Obstetrics and Gynecology, Perinatology Unit, Eskisehir Osmangazi University School of Medicine, Meselik Kampusu, Eskisehir, Turkey.
authors.forename: E
authors.initials: E
authors.lastname: Ozalp
authors.forename: H M
authors.initials: HM
authors.lastname: Tanir
authors.forename: T
authors.initials: T
authors.lastname: Sener
mesh_terms: D000282:Administration, Intravaginal; D000328:Adult; D003692:Delayed-Action Preparations; D036861:Delivery, Obstetric; D003967:Diarrhea / Q000453:epidemiology; D015232:Dinoprostone / Q000627:therapeutic use*; D005260:Female; D005334:Fever / Q000453:epidemiology; D006801:Humans; D007262:Infusions, Intravenous; D009325:Nausea / Q000453:epidemiology; D010120:Oxytocics / Q000627:therapeutic use*; D010121:Oxytocin / Q000627:therapeutic use*; D006473:Postpartum Hemorrhage / Q000517:prevention & control*; D011247:Pregnancy; D011446:Prospective Studies; D012768:Shivering; D014839:Vomiting / Q000453:epidemiology
chemical_list: D003692:Delayed-Action Preparations; D010120:Oxytocics; D010121:Oxytocin; D015232:Dinoprostone